Drug intelligence / Profile preview

Metronidazole, Clarithromycin, Ciprofloxacin, and Lansoprazole Combination

Development stage
Unknown
Lead developer
Sanofi
Modality
Drug Delivery Systems
Administration
Oral
01

Overview

This combination therapy involves four drugs: metronidazole, clarithromycin, ciprofloxacin, and lansoprazole. Based on the search results, this specific four-drug combination is **not documented as a standard regimen** for treating Helicobacter pylori (H. pylori) infections, although its individual components are used in various H. pylori eradication therapies. * **Lansoprazole** is a proton pump inhibitor (PPI) that works by decreasing stomach acid production. * **Clarithromycin** and **metronidazole** are antibiotics effective against H. pylori, utilized in standard triple therapies. * **Ciprofloxacin** is a fluoroquinolone antibiotic sometimes used in "rescue" regimens for H. pylori eradication when initial treatments fail. While a standard triple therapy uses lansoprazole, clarithromycin, and metronidazole, and a rescue regimen might use ciprofloxacin, metronidazole, and a PPI (like esomeprazole, similar to lansoprazole), the combination of all four was not found as a standard approach in the provided results. Such a combination would likely be considered for complex cases, potentially involving antibiotic resistance, but its efficacy and standard dosing were not detailed.

02

Targets

23S rRNA (23S ribosomal RNA)NeuraminidaseBacterial DNA gyrase and topoisomerase IV (DNA gyrase/Topo IV)ATP4A (Potassium–transporting ATPase alpha chain 1)

Beyond the preview

Go deeper on Metronidazole, Clarithromycin, Ciprofloxacin, and Lansoprazole Combination.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Metronidazole, Clarithromycin, Ciprofloxacin, and Lansoprazole Combination.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call